Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study

July 16, 2017 updated by: dr mohamed laban, Ain Shams University

Detection of Chlamydia DNA by Polymerase Chain Reaction ( PCR ) in Tumours Tissue of Primary Tubal and Ovarian Cancers : a Pilot Study

PCR for chlamydia DNA is done in paraffin blocks of cases of primary tubal cancer and is compared to cases of high grade serous ovarian cancer and normal tubes .

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The investigators shall review the early cancer detection unite pathology records for the past 10 years , for cases diagnosed with primary Fallopian tube cancers , cases of high and low grade serous ovarian cancer and cases underwent hysterectomy and salpingectomy for non oncological reasons. Paraffin blocks for suitable selected patients will be examined histologically to confirm the primary diagnosis . Chlamydia DNA in these paraffin blocks of the Fallopian tubes and ovarian tissues will be examined using PCR techniques . The possible correlation between the presence of Chlamydia DNA and the ovarian serous tumours and primary tubal cancer will be analyzed statistically .

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt
        • Ain Shams Maternity Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Pathology blocks of patients with primary tubal cancer and with high grade serous ovarian cancer and normal tubes.

Description

Inclusion Criteria:

  • any patient with primary tubal cancer and high grade serous cancer and normal tubes.

Exclusion Criteria:

  • clinical pelvic inflammatory disease
  • salpingectomy for ectopic

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
primary tubal cancer group
Paraffin blocks of cases of primary tubal cancer
Other: PCR for chlamydia DNA in primary tubal cancer
PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
high grade serous ovarian cancer group
Paraffin blocks of cases of high grade serous ovarian cancer
Other: PCR for chlamydia DNA in primary tubal cancer
PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
Low Grade Serous Ovarian Cancer
Paraffin blocks of cases of low grade serous ovarian cancer
Other: PCR for chlamydia DNA in primary tubal cancer
PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
normal tubes group
Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
Other: PCR for chlamydia DNA in primary tubal cancer
PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Presence of chlamydia DNA in tubal and ovarian tissues
Time Frame: Up to 24 weeks
Up to 24 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Presence of concomitant tubal cancer with high grade serous ovarian cancer
Time Frame: Up to 8 weeks
Up to 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

March 1, 2017

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

January 10, 2015

First Submitted That Met QC Criteria

January 21, 2015

First Posted (Estimate)

January 22, 2015

Study Record Updates

Last Update Posted (Actual)

July 18, 2017

Last Update Submitted That Met QC Criteria

July 16, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • lab7682

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Neoplasm of Fallopian Tube

Clinical Trials on PCR for chlamydia DNA in primary tubal cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe